Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen Hit By Enbrel 'Peculiarities' And Repatha Resistance

Apr 27 2017

• By Mandy Jackson

Arrows miss target

Related Content

PSCK9 Battle: Sanofi Not Negotiating Praluent Fate With Amgen; Ruling Possible By June

Feb 13 2017

Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?

Mar 18 2017

Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition

Oct 28 2016

Related Companies

Amgen, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Additional Topics

Commercial Sales & Earnings Market Access Reimbursement Companies BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.